Celltrion to allot cash, stock dividend at once

The company plans to grow its dividend to 30% of profit after investment

Celltrion to allot cash, stock dividend at once
Dae-Kyu Ahn 1
2024-12-13 17:17:22 powerzanic@hankyung.com
Markets

South Korea’s biosimilar maker Celltrion Inc. on Friday announced a plan to allot cash and stock dividends simultaneously. 

The company will pay a cash dividend of 750 won ($0.5) per common share and a stock dividend of 0.05 won.

The total cash dividend amount is 153.7 billion won, and the total number of dividend shares is 12.5 million.

Celltrion's dividends will be paid to shareholders on the ex-dividend date after the final approval at the annual general meeting in March next year. 

The record date is December 31. 

Previously, Celltrion decided to retire about a quarter of its treasury stock worth 563 billion won in January next year.

Since the start of this year, it has bought back about 430 billion won in shares.

The company will continue to grow its dividend to 30% of profit after investment. 

Write to Dae-Kyu Ahn at powerzanic@hankyung.com

Celltrion gets approval of Omlyclo in Canada

Celltrion gets approval of Omlyclo in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma and chronic idiopathic urticaria treatment Xolair, the company said on Monday. With this approval, Celltrion can sell Omlyclo in Canada for all

Celltrion to retire $400 mn treasury stock in January

Celltrion to retire $400 mn treasury stock in January

A bird's-eye view of Celltrion's Songdo campus in Incheon, South Korea South Korea’s biosimilar maker Celltrion Inc. on Wednesday announced a plan to retire about a quarter of its treasury stock worth 563 billion won ($400 million) in January as it is on course to achieve its largest-ever

Celltrion to break ground on CDMO plant in 2025: Chairman Seo

Celltrion to break ground on CDMO plant in 2025: Chairman Seo

Celltrion founder and Chairman Seo Jung-jin speaks at Korea Investment Week 2024, hosted by the Korea Economic Daily, on Sept. 11, 2024 South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (CDMO) plant

(* comment hide *}